Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Dyne Therapeutics Analyst Ratings and Price Targets | NASDAQ:DYN | Benzinga
Dyne Therapeutics Inc has a consensus price target of $47.31 based on the ratings of 14 analysts. The high is $66 issued by Stifel on August 16, 2024. The low is $17 issued by JP Morgan on March 21, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and JP Morgan on May 9, 2025, May 9, 2025, and March 21, 2025, respectively. With an average price target of $35 between HC Wainwright & Co., Chardan Capital, and JP Morgan, there's an implied 191.30% upside for Dyne Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
JP Morgan
BMO Capital
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Dyne Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | 216.27% | HC Wainwright & Co. | Andrew Fein55% | $46 → $38 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 316.15% | Chardan Capital | Keay Nakae55% | $50 → $50 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 41.49% | JP Morgan | Tessa Romero56% | $18 → $17 | Maintains | Neutral | Get Alert |
| 03/17/2025 | Buy Now | 282.85% | HC Wainwright & Co. | Andrew Fein55% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 316.15% | Chardan Capital | Keay Nakae55% | $50 → $50 | Maintains | Buy | Get Alert |
| 03/12/2025 | Buy Now | 316.15% | BMO Capital | Kostas Biliouris32% | → $50 | Initiates | → Outperform | Get Alert |
| 03/07/2025 | Buy Now | 316.15% | Scotiabank | Louise Chen52% | → $50 | Initiates | → Sector Outperform | Get Alert |
| 02/28/2025 | Buy Now | 316.15% | Chardan Capital | Keay Nakae55% | $50 → $50 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 299.5% | Piper Sandler | Edward Tenthoff50% | $53 → $48 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 282.85% | HC Wainwright & Co. | Andrew Fein55% | $55 → $46 | Maintains | Buy | Get Alert |
| 01/24/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay50% | — | Reiterates | Buy → Buy | Get Alert |
| 01/14/2025 | Buy Now | 274.53% | RBC Capital | Luca Issi41% | $45 → $45 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | 357.76% | HC Wainwright & Co. | Andrew Fein55% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 316.15% | Chardan Capital | Keay Nakae55% | $50 → $50 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 357.76% | HC Wainwright & Co. | Andrew Fein55% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 282.85% | Baird | Brian Skorney57% | → $46 | Initiates | → Outperform | Get Alert |
| 11/26/2024 | Buy Now | 274.53% | RBC Capital | Luca Issi41% | → $45 | Initiates | → Outperform | Get Alert |
| 11/13/2024 | Buy Now | 316.15% | Chardan Capital | Keay Nakae55% | $50 → $50 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 357.76% | HC Wainwright & Co. | Andrew Fein55% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 191.3% | JP Morgan | Tessa Romero56% | $43 → $35 | Downgrade | Overweight → Neutral | Get Alert |
| 09/23/2024 | Buy Now | 341.12% | Piper Sandler | Edward Tenthoff50% | $53 → $53 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 357.76% | HC Wainwright & Co. | Andrew Fein55% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 357.76% | Oppenheimer | Francois Brisebois40% | $55 → $55 | Reiterates | Outperform → Outperform | Get Alert |
| 08/16/2024 | Buy Now | 449.31% | Stifel | Paul Matteis43% | $41 → $66 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 316.15% | Guggenheim | Debjit Chattopadhyay50% | $45 → $50 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 332.79% | Morgan Stanley | Michael Ulz62% | $48 → $52 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 341.12% | Piper Sandler | Edward Tenthoff50% | $43 → $53 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 357.76% | HC Wainwright & Co. | Andrew Fein55% | $48 → $55 | Maintains | Buy | Get Alert |
| 07/09/2024 | Buy Now | 257.89% | JP Morgan | Tessa Romero56% | $39 → $43 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | 249.56% | Chardan Capital | Keay Nakae55% | $31 → $42 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 249.56% | Jefferies | — | $36 → $42 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 299.5% | HC Wainwright & Co. | Andrew Fein55% | $36 → $48 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 158.01% | Chardan Capital | Keay Nakae55% | $31 → $31 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 291.18% | Oppenheimer | Francois Brisebois40% | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 199.63% | HC Wainwright & Co. | Andrew Fein55% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 232.92% | Morgan Stanley | Michael Ulz62% | → $40 | Initiates | → Overweight | Get Alert |
| 03/26/2024 | Buy Now | 291.18% | Oppenheimer | Francois Brisebois40% | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 158.01% | Chardan Capital | Keay Nakae55% | $20 → $31 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | 207.95% | Guggenheim | Debjit Chattopadhyay50% | $33 → $37 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 199.63% | HC Wainwright & Co. | Andrew Fein55% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 241.24% | Stifel | Paul Matteis43% | $35 → $41 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 141.36% | Piper Sandler | Edward Tenthoff50% | $27 → $29 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 291.18% | Oppenheimer | Francois Brisebois40% | $44 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 199.63% | HC Wainwright & Co. | Andrew Fein55% | → $36 | Initiates | → Buy | Get Alert |
| 01/04/2024 | Buy Now | 366.08% | Raymond James | Steven Seedhouse57% | $27 → $56 | Maintains | Strong Buy | Get Alert |
| 08/09/2023 | Buy Now | 83.1% | JP Morgan | Tessa Romero56% | $20 → $22 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 66.46% | Chardan Capital | Keay Nakae55% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2023 | Buy Now | 66.46% | Chardan Capital | Keay Nakae55% | $17 → $20 | Maintains | Buy | Get Alert |
| 02/27/2023 | Buy Now | 124.72% | Raymond James | Steven Seedhouse57% | $16 → $27 | Upgrade | Outperform → Strong Buy | Get Alert |
| 02/15/2023 | Buy Now | 182.98% | Oppenheimer | Francois Brisebois40% | → $34 | Initiates | → Outperform | Get Alert |
| 01/26/2023 | Buy Now | 174.66% | Guggenheim | Debjit Chattopadhyay50% | → $33 | Initiates | → Buy | Get Alert |
| 11/29/2022 | Buy Now | 49.81% | JP Morgan | Tessa Romero56% | $24 → $18 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 33.17% | Raymond James | Steven Seedhouse57% | $15 → $16 | Maintains | Outperform | Get Alert |
| 07/20/2022 | Buy Now | 41.49% | Chardan Capital | Keay Nakae55% | → $17 | Initiates | → Buy | Get Alert |
| 07/12/2022 | Buy Now | 24.84% | Raymond James | Steven Seedhouse57% | → $15 | Initiates | → Outperform | Get Alert |
| 05/23/2022 | Buy Now | -0.12% | Piper Sandler | Edward Tenthoff50% | $16 → $12 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Dyne Therapeutics (DYN) stock?
The latest price target for Dyne Therapeutics (NASDAQ:DYN) was reported by HC Wainwright & Co. on May 9, 2025. The analyst firm set a price target for $38.00 expecting DYN to rise to within 12 months (a possible 216.27% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dyne Therapeutics (DYN)?
The latest analyst rating for Dyne Therapeutics (NASDAQ:DYN) was provided by HC Wainwright & Co., and Dyne Therapeutics maintained their buy rating.
When was the last upgrade for Dyne Therapeutics (DYN)?
The last upgrade for Dyne Therapeutics Inc happened on February 27, 2023 when Raymond James raised their price target to $27. Raymond James previously had an outperform for Dyne Therapeutics Inc.
When was the last downgrade for Dyne Therapeutics (DYN)?
The last downgrade for Dyne Therapeutics Inc happened on October 24, 2024 when JP Morgan changed their price target from $43 to $35 for Dyne Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Dyne Therapeutics (DYN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dyne Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dyne Therapeutics was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating Dyne Therapeutics (DYN) correct?
While ratings are subjective and will change, the latest Dyne Therapeutics (DYN) rating was a maintained with a price target of $46.00 to $38.00. The current price Dyne Therapeutics (DYN) is trading at is $12.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
